Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Georgina Long

Georgina Long

BSc, PhD, MBBS, FRACP, FAHMS
The University of Sydney, North Sydney, Australia
Challenges associated with implementing ctDNA approaches in melanoma 0:36
Challenges associated with implementing ctDNA approaches in melanoma
Georgina Long • 10 Sep 2022
Treating patients with melanoma who progressed on anti-PD-L1 with lenvatinib and pembrolizumab 0:56
Treating patients with melanoma who progressed on anti-PD-L1 with lenvatinib and pembrolizumab
Georgina Long • 10 Sep 2022
Pre-treatment ctDNA linked to increased risk of early recurrence in IO-treated melanoma 2:01
Pre-treatment ctDNA linked to increased risk of early recurrence in IO-treated melanoma
Georgina Long • 10 Sep 2022
NeoPeLe: neoadjuvant pembrolizumab and lenvatinib in resectable stage III melanoma 1:20
NeoPeLe: neoadjuvant pembrolizumab and lenvatinib in resectable stage III melanoma
Georgina Long • 10 Sep 2022
The current and future treatment of metastatic melanoma 4:40
The current and future treatment of metastatic melanoma
Georgina Long • 13 Apr 2021
5-year follow-up: dabrafenib plus trametinib reduces relapse risk in melanoma 0:56
5-year follow-up: dabrafenib plus trametinib reduces relapse risk in melanoma
Georgina Long • 13 Apr 2021
Melanoma news from ESMO 19 1:06
Melanoma news from ESMO 19
Georgina Long • 28 Sep 2019
POLARIS: encorafenib/binimetinib for advanced BRAFV600+ melanoma 0:53
POLARIS: encorafenib/binimetinib for advanced BRAFV600+ melanoma
Georgina Long • 28 Sep 2019
Long-term outcomes of nivo vs. nivo/ipi in melanoma brain metastases: ABC trial data 2:45
Long-term outcomes of nivo vs. nivo/ipi in melanoma brain metastases: ABC trial data
Georgina Long • 28 Sep 2019
OpACIn-neo trial RFS and biomarker analyses: optimal neoadjuvant ipi/nivo dosing in melanoma 2:52
OpACIn-neo trial RFS and biomarker analyses: optimal neoadjuvant ipi/nivo dosing in melanoma
Georgina Long
COMBI-i findings 2:37
COMBI-i findings
Georgina Long • 2 Jun 2019
KEYNOTE-029: pembrolizumab with ipilimumab for melanoma 2:34
KEYNOTE-029: pembrolizumab with ipilimumab for melanoma
Georgina Long • 2 Jun 2019
COMBI-AD: QoL of patients 1:14
COMBI-AD: QoL of patients
Georgina Long • 2 Jun 2019
Preventing melanoma through public health education 1:36
Preventing melanoma through public health education
Georgina Long • 27 Jan 2017
Unmet needs in melanoma 1:15
Unmet needs in melanoma
Georgina Long • 27 Jan 2017
KEYNOTE-006: the efficacy of ipilimumab after pembrolizumab in patients with advanced melanoma 3:35
KEYNOTE-006: the efficacy of ipilimumab after pembrolizumab in patients with advanced melanoma
Georgina Long • 27 Jan 2017
The content of VJOncology is intended for healthcare professionals